



ACADEMICIA
An International
Multidisciplinary
Research Journal
(Double Blind Refereed & Peer Reviewed Journal)



DOI: **10.5958/2249-7137.2021.00880.6**

**ENDOTHELIAL DYSFUNCTION AS A LINK IN THE PATHOGENESIS
OF ANKYLOSING SPONDYLITIS AGAINST THE BACKGROUND OF A
NEW CORONAVIRUS INFECTION**

M.B. Rakhimova* ; Kh.S. Akhmedov ; Y. A. Turaev*****

^{1,3}Department of Internal Diseases №3,
Tashkent Medical Academy,
Tashkent, UZBEKISTAN

ABSTRACT

The main purpose of this work was to substantiate the feasibility and possible directions of the influence of means of pharmacological correction of endothelial dysfunction for the prevention of pathological conditions associated with a new coronavirus infection. The analysis of the available literature on the functions of the endothelium was carried out, the study of foreign and domestic experience on the possible directions of pharmacological correction of endothelial dysfunction was carried out. A review of the available literature data on endothelial dysfunction with substantiation of the role of vascular endothelial damage as one of the central links in the pathogenesis of acute respiratory distress syndrome is presented. The phases of the formation of stages of endothelial dysfunction are shown, the mechanisms of endothelial damage in a new coronavirus infection are determined. Possible directions for the pharmacological correction of endothelial dysfunction are proposed, which will prevent the risk of complications from a new coronavirus infection, including through the development of pathogenetically grounded directions of pharmacotherapy.

KEYWORDS: *Ankylosing spondylitis, Asymmetric dimethylarginine, homocysteine, endothelial dysfunction, cardiovascular pathology, COVID-19.*

REFERENCES

1. Balabanova R.M., Dubinina T.V., JerdesSh.F. The dynamics of the incidence of rheumatic diseases of the adult population of Russia in 2010-2014. *Nauchno-prakticheskayarevmatologiya*. 2016. 54 (3). 266-270.
2. Poddubnyj D.A., Rebrov A.P. Cardiovascular risk in patients with ankylosing spondylitis: the role of systemic inflammation and endothelial dysfunction. *RegionalnajaFarmakoterapija v Kardiologii*. 2008.
3. Han C., Robinson D.W. Jr., Hackett M.V. Paramore L.C., Fraeman K.H., Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J. Rheumatol*. 2006.33 (11). 2167-2172.
4. Peters M.J., Visman I., Nielen M.M., Dillen N.V., Verheij R.A., Horst-Bruinsma I.E., Dijkmans B.A., Nurmohamed M.T. Ankylosing spondylitis: a risk factor for myocardial infarction? *Ann Rheum Dis*. 2010. 69 (3). 579-581.
5. ErdesSh.F. Basic principles of therapy of ankylosing spondylitis (Bekhterev's disease). *Nauchno-prakticheskayarevmatologiya*. 2013. 51 (6). 686-695.
6. Rebrov A.P., Gajdukova I.Z., Poddubnyj D.A. Cardiovascular pathology in patients with ankylosing spondylitis. *Nauchno-prakticheskayarevmatologiya*. 2012. 51 (2).
7. Poloneckij O.L., Poloneckij L.Z. Endothelial dysfunction and atherosclerosis. *Medicinskienovosti*. 2012.
8. AlekseenkoE.Yu., Govorin A.V. Condition of endothelial function in patients with primary osteoarthritis. *Sibirskijmedicinskijzhurnal (Irkutsk)*. 2010.
9. MaslyanskiyAL, Zvartau NE, Kolesova EP, Bezkishky EN, Shevchuk IA, VasilievaEYu,Mazurov VI, Konradi AO. Endothelial function in patients with rheumatologic diseases. *Arterial'nayaGipertenziya = Arterial Hypertension*. 2015. 21 (2).
10. Manuhina E.B., MalyshevL.Ju. The role of nitric oxide in the development and prevention of endothelial dysfunction. *Vestnik VGMU*. 2003. 2. 5-17.
11. Ogawa T., Kimoto M., Watanabe H. and Sasaoka K. Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats. *Arch BiochemBiophys*. 1987. 252. 526-537.
12. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme,NG-dimethylargininedimethylaminohydrolase, from rat kidney. *J Biol Chem*. 1989. 264. 10205-10209.
13. Ogawa T., Kimoto M., and Sasaoka K. Dimethylarginine: pyruvate aminotransferase in rats. Purification, properties, and identity with alanineglyoxylate aminotransferase 2. *J Biol Chem*. 1990. 265. 20938-20945.
14. Leiper J.M., Santa M., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S. and Vallance P. Identification of two human dimethylargininedimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. *Biochem J*. 1999. 343. Pt1:209-214.

15. Tran C.T., Fox M.F., Vallance P. and Leiper J.M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. *Genomics*. 2000. 68.101-105.
16. Achan V., Dayoub H., Adimoolam S., Jacobi J., Stuehlinger M. C., Wang B.Y. Dimethylargininedimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. *Circulation*. 2003. 108. 3042-3047.
17. Hasegawa K., Wakino S., Tatematsu S., Yoshioka K., Homma K., Sugano N., Kimoto M., Hayashi K., Itoh H. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylargininedimethylaminohydrolase 2. *Circ Res*. 2007. 101. 2-10.
18. Maas R. Pharmacotherapies and their influence on asymmetric dimethylarginine (ADMA). *Vasc Med*. 2005. 10. 49-57.
19. Kostourou V., Robinson S.P., Cartwright J.E., and Whitley G.S. Dimethylarginine enhances tumor growth and angiogenesis. *Br J Cancer*. 2002. 87. 673-680.
20. Lee I.S., Nishikimi M., Inoue M., Muragaki Y., and Ooshima A. Specific expression of alanineglyoxylate aminotransferase -2 in the epithelial cells of Henle's loop. *Nephron*. 1999. 83. 184-185.
21. Chen J.W., Hsu N.W., Wu T.C., Lin S.J., and Chang M. S. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. *Am J Cardiol*. 2002. 90. 974-982.
22. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N (G), N (G) -dimethylarginine in human essential hypertension. *Am J Hypertens*. 2002. 15. 590-593.
23. Stein J.H., Patrick E., McBride P.E. Hyperhomocysteinemia and Atherosclerotic Vascular Disease Pathophysiology, Screening, and Treatment *Arch Intern Med*. 1998. 158 (12). 1301-1306. doi:10.1001/archinte.158.12.1301.
24. Manak N.A. Modern views on the prevention of coronary heart disease. *Medicinskienovosti*. 2003. 5.
25. Zhloba A.A. The role of ADMA as an endogenous inhibitor of No one of the mediators of the development of vasomotor endothelial dysfunction. *Regionarnoekrovoobrashchenieimikrocirkulyaciya*. 2007. 3. 4-14.
26. Shishkin A.N., Lyndina M.L. Endothelial dysfunction and hypertension. *Arterial'najagipertenzija*. 2008. 4. 315-319.
27. Adam Kemeny-Beke, Rudolf Gesztelyi, NóraBodnár, SándorSzántó. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parameters. *Joint, Bone, Spine*. 2011. 78(2). 184-187.
28. Gian Luca Erre, Pietro S. Sanna, Angelo Zinellu, Alessandra Ponchiatti, PatriziaFenu, Salvatore Sotgia, CiriacoCarru, Antonello Ganau, Giuseppe Passiu. Plasma asymmetric

dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. *Clinical Rheumatology*. 2011. 30 (1). 21-27.

29. Egudina E.D., Sinjachenko O.V., Ermolaeva M.V., Chernyshova O.E., Polesova T.R., Khani-ukov A.A. Vascular-rheological properties of blood in ankylosing spondylitis. *Travma*. 2017. 1. 80-86. in Russian.
30. Poddubnyj D.A., Rebrov A.P. Hypertrophy and remodeling of the left ventricle in patients with ankylosing spondylitis: the role of endothelial dysfunction. *Sibirskij medicinskij zhurnal*. 2007.